<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Because of surveillance strategies in patients with known <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, more patients with high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or early <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in the distal esophagus and at the esophagogastric junction are identified </plain></SENT>
<SENT sid="1" pm="."><plain>The need for and extent of lymphadenectomy in such patients are controversial </plain></SENT>
<SENT sid="2" pm="."><plain>The technique of sentinel lymph node dissection (SLND) to diagnose early lymphatic spread is applied increasingly in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> of the gastrointestinal tract </plain></SENT>
<SENT sid="3" pm="."><plain>The poorly defined lymphatic drainage of the esophagogastric junction has so far prevented many investigators from performing SLND in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> of this anatomic region </plain></SENT>
<SENT sid="4" pm="."><plain>We report the first results of SLND in Barrett's and cardia <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The preliminary experience indicates that the method is, even in this anatomical area, feasible and yields good results in early <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>In advanced <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, the method lacks sensitivity </plain></SENT>
<SENT sid="7" pm="."><plain>Mapping should be done with blue dye and a radiocolloid </plain></SENT>
<SENT sid="8" pm="."><plain>The concept of sentinel lymph node mapping and detection thus may open the door to individualized therapy for patients with high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> in a <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> or with early Barrett's and cardia <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>